How long should patients take medications for postmenopausal osteoporosis?

Joint Bone Spine

Volumn 74, Issue 1, 2007, Pages 24-31

  Briot, Karine ^a   Trémollières, Florence ^b   Thomas, Thierry ^c   Roux, Christian ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Paul Sabatier University   (France)

^c SERVICE DE NEUROLOGIE   (France)

Author keywords

Bisphosphonates; Bone mineral density; Postmenopausal osteoporosis; SERM; Vertebral fracture

Indexed keywords

ALENDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

BONE DENSITY; COURSE EVALUATION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; JAW DISEASE; MUSCLE CRAMP; PATIENT ASSESSMENT; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; SHORT SURVEY; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; ETIDRONIC ACID; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT; TERIPARATIDE; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33847041451     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2006.05.011     Document Type: Short Survey

References (37)

1. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
2. Harris S.T., Watts N.B., and Genant H.K. Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282 (1999) 1344-1352
3. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
4. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 282 (1999) 637-645
5. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350 (2004) 459-468
6. Liberman U.A., Weiss S.R., Bröll J., Minne H.W., Quan H., Bell N.H., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333 (1995) 1437-1443
7. Cummings S.R., Black D.M., Thompson D., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
8. Tonino R.P., Meunier P.J., Emkey R., Rodriguez-Portales J.A., Menkes C.J., Wasnich R.D., et al. Skeletal benefits of alendronate: a 7-year treatment of postmenopausal women. J Clin Endocrinol Metab 85 (2000) 3109-3115
9. Bone H.G., Hosking D.H., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 (2004) 1189-1199
10. Ott S.M. Fractures after long-term alendronate therapy. J Clin Endocrinol Metab 86 (2001) 1835-1836
11. Lindsay R., Pack S., and Li Z. Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteopororsis. Osteoporos Int 16 (2005) 306-312
12. Ensrud K.E., Barrett-Connor E.L., Schwartz A., Santora A.C., Bauer D.C., Suryawanshi S., et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19 (2004) 1259-1269
13. Black D., Schwartz A., Ensrud K., Ryback-Feiglin A., Gupta J., Lombardi A., et al. A 5 year randomized trial of the long-term efficacy and safety of Alendronate: the FIT Long-Term Extension (FLEX). J Bone Miner Res 19 (2004) S45
14. Reginster J.Y., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11 (2000) 83-91
15. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al. Hip intervention program study group: effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. N Engl J Med 344 (2001) 333-340
16. Sorensen O.H., Crawford G.M., Mulder H., Hosking D.J., Gennari C., Mellsröm D., et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32 (2003) 120-126
17. Mellstrom D., Sorensen O.H., Goemaere S., Roux C., Johnson T.D., and Chines A.A. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcified Tissue International 75 (2004) 462-468
18. Mortensen L., Charles P., Bekker P.J., Digennaro J., and Johnston Jr. C.C. Risedronate increases bone mass is early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 83 (1998) 396-402
19. Roschger P., Rinnerthaler S., Yates J., Rodan G.A., Fratzl P., and Klaushofer K. Alendronate increases degree and uniformity of mineralization of cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29 (2001) 185-191
20. Borah B., Dufresne T.E., Chmielewski P.A., Gross G.J., Prenger M.C., and Phipps R.J. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 17 (2002) 1139-1147
21. Otomo H., Sakai A., Ikeda S., Tanaka S., Ito M., Phipps R.J., et al. Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2. J Bone Miner Metab 22 (2004) 404-414
22. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates A.J., and Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27 (2000) 686-694
23. Dufresne T.E., Chmielewski P.A., Manhart M.D., Johnson T.D., and Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 73 (2003) 423-432
24. Ste-Marie L.G., Sod E., Johnson T., and Chines A. Five years of treatment with risedronate an its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 75 (2004) 469-476
25. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Jacob D.S., Johnston C.C., et al. Effects of high-dose etidronate treatment on microdamage accumulation and biochemical properties in beagle bone before occurrence of spontaneous fractures. Bone 29 (2001) 271-278
26. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C., and Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biochemical properties in clinically relevant skeletal sites in beagles. Bone 28 (2001) 524-531
27. Akkus O., Polyakova-Akkus A., Adar F., and Schaffler M.B. Aging of microstructural compartments in human compact bone. J Bone Miner Res 18 (2003) 1012-1019
28. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., and Pak C.Y.C. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90 (2005) 1294-1301
29. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
30. Khan S.A., Kanis J.A., Vasikaran S., Kline W.F., Matuszewski B.K., McCloskey E.V., et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12 (1997) 1700-1707
31. Delmas P.D., Ensrud K.E., Adachi J.D., Harper K.D., Sarkar S., Gennari C., et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87 (2002) 3609-3617
32. Martino S., Cauley J.A., Barrett-Connor E., Powles T.J., Mershon J., Disch D., et al. Continuing Outcomes Relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96 (2004) 1751-1761
33. Siris E.S., Harris S.T., Eastell R., Zanchetta J.R., Goemaere S., Diez-Perez A., et al. Cummings SR and For the Continuing Outcomes Relevant to Evista (CORE) Investigators. Skeletal effects of Raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res 20 (2005) 1514-1524
34. Neele S.J., Evertz R., De Valk-De Roo G., Roos J.C., and Netelenbos J.C. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 30 (2002) 599-603
35. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized study. JAMA 281 (1999) 2189-2197
36. Lindsay R., Scheele W.H., Neer R., Pohl G., Adami G., Mautalen C., et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164 (2004) 2024-2030
37. Reginster J.Y., Seeman E., De Vernejoul M.C., Adami S., Compston J., Phenekos C., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90 (2005) 2816-2822